J&J is home to globally known household products such as Tylenol pain medication and Aveeno body lotion. But over the past year, its health care and pharmaceutical businesses made the most news. The company began distributing its Janssen single-dose COVID-19 vaccine in March 2021. Manufacturing problems and the vaccine’s lower efficacy compared with products from Pfizer-BioNTech and Moderna hindered its adoption, but as of May 2022 about 19 million doses had been administered in the U.S., and millions more internationally. In July 2021, J&J agreed to pay up to $5 billion as part of a nationwide settlement agreement to fund state and local efforts to address the opioid crisis. (The company admitted no wrongdoing related to marketing of its pain medications.) And in November 2021 the company announced that it would essentially become a pharma pure play; by late 2023, J&J will spin off its consumer products businesses as a separate company. 
Nikos Pekiaridis—SOPA Images/LightRocket via Getty Images

Company Information

As of 2/1/2023
Country
U.S.
Headquarters
New Brunswick, N.J.
Industry
Pharmaceuticals
CEO
Joaquin Duato
Company Type
Public
Ticker
JNJ
Revenues ($M)
$94,943
Profits ($M)
$17,941
Market Value ($M)
$441,168
Employees
141,700
Figures are for fiscal year ended Dec. 31, 2022. Market value as of Jan. 20, 2023. Sources: Bloomberg; S&P Global.

Key Financials (Last Fiscal Year)

$ millions
% change
Revenues ($M)
$93,775
13.6%
Profits ($M)
$20,878
41.9%
Assets ($M)
$182,018
-
Total Stockholder Equity ($M)
$74,023
-

Profit Ratios

Profit as % of Revenues
22.3%
Profits as % of Assets
11.5%
Profits as % of Stockholder Equity
28.2%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)
781
EPS % Change (from 2020)
41.7%
EPS % Change (5 year annual rate)
5.7%
EPS % Change (10 year annual rate)
8.4%

Total Return

Total Return to Investors (2021)
11.5%
Total Return to Investors (5 year, annualized)
11.1%
Total Return to Investors (10 year, annualized)
13.2%

Johnson & Johnson Rank History

Historical Data

YearRevenues ($M)Profits ($M)Assets ($M)Total Stockholder Equity ($M)
2021$82,5840.6%$14,714-2.7%$174,894$63,278
2020$82,0590.6%$15,119-1.2%$157,728$59,471
2019$81,5816.7%$15,2971076.7%$152,954$59,752
2018$76,4506.3%$1,300-92.1%$157,303$60,160
2017$71,8902.6%$16,5407.3%$141,208$70,418
SHOW MORE
FortuneDataStore ad
Lists ranking Johnson & Johnson
RANK37
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE
RANK107
Global 500 - 2022Aggregate sales hit $37.8 trillion last year—an in...READ MORE
RANK22
World's Most Admired Companies - 2023The 25th Fortune World’s Most Admired Companies li...READ MORE